1109 Chemerin suppresses prostate tumor growth by modulating the recruitment of effector NK and CD8+ T-cells into the tumor microenvironment by Bo Peng, Russell Pachynski, Kevin Kim, Muhammad A Saeed

#8. Radium-223 treated primary patient bone biopsy analysis: Macro to microscale analyses and dosimetry by Nadia Benabdallah, Peng Lu, Jeff Michalski, Brian Baumann, Russell Pachynski, Jack Jennings, Robert F. Hobbs, Daniel L.J. Thorek

Get full text

377 IL-15 treatment enhances the in vivo anti-tumor efficacy of sipuleucel-T by activating CD8+ T and NKT effector cells, augmenting tumor infiltration, and reversing immunoresista... by Bo Peng, Tuyen Vu, Nadeem Sheikh, Russell Pachynski, Brian Van Tine, Todd Fehniger, Kevin Kim, Muhammad A Saeed, Ariel Borkowski, Daniel Thorek

759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors by Lawrence Fong, Sumit Subudhi, Gerald S Falchook, Russell Pachynski, Anthony El-Khoueiry, Ian Walters, Robert Krämer, Sushant Kumar, Kasim Mookhtiar, Justin Fairchild, Mohamad A Salkeni, Jaspreet Grewal, William Tester, Samik Upadhaya, Ana Rosa Saez Ibanez, Desa Rae Stanton-Pastore

665 Immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer: A clinical trial in progress by Neal Shore, Robert Dreicer, Matthew Zibelman, Mark N Stein, Ralph J Hauke, Russell Pachynski, Bethan Jones, Jessica Hawley, Charlotte Davis, Katie Anderson, Antonella Vardeu, Margaret A Marshall, Vicky Wheeler, Sarah Sebastian, Kevin Kayvan Zarrabi, Brian Miles, Jennifer Bendall